IDBS bloggSex viktiga skäl till att övergå från ett lokalt till ett molnbaserat system för hantering av laboratoriedata

IDBS Blog | 14 June 2024

Sex viktiga skäl till att övergå från ett lokalt till ett molnbaserat system för hantering av laboratoriedata

Transition to the cloud

By Chris Ovett, Lead Platform Product Manager, IDBS

The laboratory informatics software market is estimated to grow 6.1% annually, totaling USD 3 billion in 2028.1 Within this, the electronic laboratory notebook (ELN) and laboratory execution system (LES) market is expected to be the fastest growing, increasing 9% annually. 

Although the trend towards cloud-based ELN deployments is becoming stronger, with cloud representing about 70% of the market, there are still some organizations that are hesitant to implement and adopt cloud-based laboratory data management systems. There are foundational reasons to make the switch, such as enabling scalability, making it easier to integrate data and saving IT resources, but here we dig deeper into some other compelling reasons to move from on-premise to a cloud-based laboratory data management system. 


1. Advanced security 

As with all biopharmaceutical discoveries and developments, data is at the heart of everything. Being able to rely on data integrity throughout the supply chain is vital to building confidence in the product and company. However, many researchers still depend on disparate systems and manual data input which introduces opportunities for errors and can result in Food & Drug Administration (FDA) warning letters, fines or recalls. 

Implementing a cloud-based data management system helps customers stay up to date on the latest security measures without dedicated staff, and – with the right partner – get a level of data protection that an individual company might find prohibitively expensive to implement on-premises.  

2. Agile scalability and reduced IT burden

The cost of bringing a new biopharma product to market can total close to USD 2 billion.2 Therefore, drug developers and manufacturers are always looking for ways to lower costs or prevent incurring additional costs. By adopting a cloud-based system to manage data, users can securely access data from anywhere, streamlining operations and ultimately accelerating their time to market. 

Cloud systems can scale automatically to meet the needs of the business, including the fast addition of new users. This significantly reduces IT overhead in maintenance and procurement. Additionally, cloud-based deployment removes the need for servers that have to be maintained to ensure optimal data reliability and security. 

3. Drive innovation

Compliance with standards such as 21 Code of Federal Regulations (CFR) Part 11 and EudraLex Annex 11 is critical for the BioPharma industry, with organizations open to strict and extensive penalties if failing to comply. For instance, manual data transcription workflows require extensive additional quality checks to ensure data integrity and that they meet regulatory requirements, such as 21 CFR Part 11 or good laboratory/manufacturing practices (GxP). 

A cloud-based laboratory data management system can increase the pace of innovation, with the ability to adopt the latest features and technologies quicker with minimal downtime for the business. Data is secured in a closed system that restricts access, only allowing authorized personnel to input, edit or access data, with time stamps and electronic signatures. 

4. Protect your data

In the BioPharma industry, data security is a priority, especially when outsourcing data to third-party companies such as contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Threats to data integrity put all parties at risk and cloud-based programs can help to protect against highly perilous events. 

Software as a service (SaaS) solutions enable customers to use their cloud service provider to develop integrated disaster recovery plans that are more robust and cost-effective than on-premise options. Cloud-based systems are automatically backed up and updated regularly, without relying on laboratory personnel.  

Platforms must adhere to industry standards such as the International Organization for Standardization (ISO) 27001 for information security management that promotes a robust risk management approach to current and future threats applying to people and technologies, as well as data security policies. 

5. Enhance collaboration

Both small and medium BioPharma and large enterprises need to collaborate with people and share data, whether that’s outside of their own organizations, such as with a CRO, CDMO or customer, or with colleagues across departments and geographies. Being able to securely share information across the supply chain can facilitate stronger relationships, improve laboratory productivity and speed up time to market. 

Storing data digitally in a cloud-based data management system means that laboratory personnel can share data sets, pages or even entire notebooks that are in a standardized format securely and easily across the globe. It can also support robust reporting and provide evidence that might be required by regulatory bodies, external partners or collaborators. 

6. Help to meet sustainability goals

Sustainability, safety and reusability are becoming more pertinent considerations when bringing a new biopharma product to market. The global BioPharma industry is responsible for producing large amounts of waste and emissions and only t10% of publicly owned biotechnology and pharmaceutical companies are on track to meet the Paris 2030 Climate Goal. 

Effectively managing data in the cloud can help companies meet their sustainability goals by enabling them to store data in a centralized location and streamline workflows to increase reproducibility, therefore, avoiding waste of resources.  

IDBS Polar 

Innovative BioPharma companies are embracing solutions that include cloud-based digital workflows designed to create robust data throughout the product lifecycle. This provides a solid foundation for analytics, accelerated time to market and adherence to regulatory compliance while minimizing costs and data security risks. 

IDBS Polar is a BioPharma Lifecycle Management (BPLM) platform for data capture, process execution, advanced analysis, data visualization and reporting across the läkemedelsutveckling lifecycle. The combination of experimental- and model-based outcomes eliminates manual processes and makes digital workflows more efficient and seamless. The world’s first BPLM platform allows scientists to efficiently execute processes while curating the data needed to accelerate time to market. 


Want to hear more about how cloud-based deployments can enhance your biopharma business, join our upcoming webinar.


Om författaren

Chris Ovett - Move to cloud-based lab data management platformChris Ovett is the Senior Product Manager for the IDBS Cloud Platform. He is accountable for defining IDBS strategy and executing the roadmap for the underpinning technology and process that enables teams across IDBS to deliver novel products and solutions to our customers.   A versatile leader with over twenty years of experience in Product, Solution Architecture, Engineering and Services who places customers at the core, leading them through all stages of their digital journey. 





  1. Top-Down Analytics. (2023). Laboratory Data Management Software Market Forecast 2023-2028. Retrieved July 2023.
  2. Sabatini, M.T., & Chalmers, M. (2023). The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies. Pharm Med, 37, 365–375.
Kolla in vår bloggsektion för mer av den här typen

Fler nyheter